Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs

(2012) E. M. J. Bindels et al.   BLOOD

Prdm3 and Prdm16 are H3K9me1 Methyltransferases Required for Mammalian Heterochromatin Integrity

(2012) Inês Pinheiro et al.   CELL

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML

(2012) A V Krivtsov et al.   LEUKEMIA

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

(2012) Jolanta Grembecka et al.   Nature Chemical Biology

Targeting a DNA Binding Motif of the EVI1 Protein by a Pyrrole–Imidazole Polyamide

(2011) Yi Zhang et al.   BIOCHEMISTRY

PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function

(2011) Y. Zhang et al.   BLOOD

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

(2011) Scott R. Daigle et al.   CANCER CELL

Early mammalian erythropoiesis requires the Dot1L methyltransferase

(2010) Y. Feng et al.   BLOOD

Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells

(2010) S. Arai et al.   BLOOD

Structural Biology of Human H3K9 Methyltransferases

(2010) Hong Wu et al.   PLoS One

Malignant Transformation Initiated by Mll-AF9: Gene Dosage and Critical Target Cells

(2008) Weili Chen et al.   CANCER CELL

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

(2008) Zhong Wang et al.   NATURE

The Histone H3K79 Methyltransferase Dot1L Is Essential for Mammalian Development and Heterochromatin Structure

(2008) Brendan Jones et al.   PLoS Genetics